Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Tianjin SinoBiotech Ltd.
* Brief Protocol: Treat the patients taking Taxotere+Epirubicin +Cyclophosphamide (TEC) treatment or Taxotere+Epirubicin (TE)treatment chemotherapy with the study medicine or positive control during the period between two chemotherapy treatments.
* Targeted patients: breast cancer
* Subjects were randomly divided into two groups. The test group received recombinant human serum albumin / granulocyte thorns for injection Stimulant fusion protein 2.4mg treatment. Positive control group received recombinant human granulocyte colony stimuli Factor injection therapy
* Number of patients: 80
Age
18–65
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Age 18-65.
Diagnosed breast cancer, suitable for TEC or TE .
ECOG performance status 0 or 1.
Adjuvant chemotherapy; new adjuvant chemotherapy; newly diagnosed class Ⅳ and prior chemotherapy.
No obvious abnormal ecg examination.
TBIL, ALT, AST≤2.5×ULN (≤5×ULN if presence of hepatic metastases).
